CurifyLabs Funding News – Finnish Healthtech Company CurifyLabs Secures €6.7M

Their goal is to make these custom medications safer and more tailored to each patient's needs. With this new round, the company’s total funding now stands at €17.6 million.

Compounded medications are essential when standard drugs don’t work for a patient—due to dosage needs, allergies, or drug shortages.

Read More - SpAItial Funding News- SpAItial Raises $13M Seed Funding For AI-native 3D Applications

Normally, doctors prescribe the medicine, and pharmacists manually measure and mix the ingredients to make it. But this process is slow, expensive, and especially important for vulnerable groups like children and cancer patients.

Today, 50% of medicines aren’t available in child-friendly doses or forms. And although demand is growing, only 1% of drugs are currently personalized through compounding.

Charlotta Topelius, CEO and Co-founder of CurifyLabs, says the current way of making compounded medicines is outdated, inefficient, and too reliant on manual work. It often leads to human errors and inconsistent quality.

“Patients with serious conditions may not receive accurate dosages tailored to critical factors like age, weight, and disease severity.

The consequences are real: a 9-month-old baby with cancer, for example, cannot swallow standard tablets and requires a carefully customised formulation. It’s time to work together and modernise how we deliver personalised medicine – because every patient deserves treatment that truly fits their needs.”

CurifyLabs, in collaboration with pharmacists and backed by 10 years of research, has developed a system to automate the production of compounded medicines. This solution makes the process four times faster and allows for flexible, personalized dosing.

Their Compounding System combines carrier agents, active ingredients, hardware, software, and quality control to automate the entire process of making custom medicines.

CurifyLabs uses high-quality excipient bases (inactive carrier agents) mixed with active ingredients from raw materials or crushed tablets. This mixture is then turned into tablets or liquid using the Pharma Printer—a compact, desktop compounding robot.

A cloud-based formulation library helps pharmacists follow a validated process, while built-in quality control tools ensure consistency and reduce the chance of human error.

Along with the new funding, CurifyLabs has launched RoboPharma, a €5.6 million project funded by the EU. The goal is to build a decentralized medicine manufacturing system using AI and robotics.

Supported by the EU4Health program, the project tackles a major issue in European healthcare—the weakness of centralized drug supply chains during emergencies like pandemics, natural disasters, or global disruptions.

The RoboPharma project is led by CurifyLabs and involves six partners. Its goal is to improve crisis readiness across Europe by enabling on-site medicine production.

The funding round was led by Springvest and included a €1 million deep tech loan from Business Finland.

According to Aki Soudunsaari, CEO of Springvest Plc,

“We’re seeing rapid growth of the global compounding market which presents an exceptional opportunity for new solutions that have the potential to be ten times better than the existing ways to solve the same challenges.

Simultaneously, CurifyLabs’ entry into the US market, where the vast majority of compounding manufacturing occurs, positions CurifyLabs for substantial growth."

The funding will help CurifyLabs grow its operations and attract large-scale customers.

About CurifyLabs

CurifyLabs was founded in 2021 by Charlotta Topelius and Niklas Sandler Topelius. CurifyLabs is a Finnish healthtech company creating solutions to make personalized medicines in pharmacies and hospitals. They are changing how personalized medicines are made by offering technology that automates the compounding process. This turns a slow, manual task into a fast, easy, and accurate system.